<DOC>
	<DOCNO>NCT00257660</DOCNO>
	<brief_summary>The aim study demonstrate effectiveness safety 500 unit Dysport manufacture new manufacture facility Europe .</brief_summary>
	<brief_title>Randomized , Placebo-Controlled Study AbobotulinumtoxinA ( DysportÂ® ) Treatment Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Cervical dystonia least 18 month since onset , previously untreated botulinum toxin previously treat botulinum toxin type A B minimum interval 16 week since last injection return least usual pretreatment status TWSTRS severity , disability total score meeting define criterion baseline Pure anterocollis pure retrocollis In apparent remission cervical dystonia Previous poor response last two botulinum toxin type A type B treatment Being treat type B toxin due lack efficacy type A toxin know neutralizing antibody type A toxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>